Doxycycline Hyclate Contract Award SPE2D2-25-D-0015

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D2-25-D-0015

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

Laurelton, New York, UNITED STATES

SourceSAM
Documents2
The Defense Logistics Agency (DLA) Troop Support, operating under the Department of Defense, has issued an award notice for contract SPE2D2-25-D-0015, pertaining to the supply of Doxycycline Hyclate. This contract falls under the North American Industry Classification System (NAICS) code 325412, which covers Pharmaceutical Preparation Manufacturing, and is further classified by Product Service Code 6505, indicating drugs and biologicals. The notice announces the execution of Option #1 for the contract, extending the performance period from July 2, 2026, through July 1, 2027. All other terms and conditions of the contract remain unchanged, ensuring continuity in the scope and requirements established in the original agreement. The place of performance is specified as Laurelton, New York, United States, which will serve as the primary location for contract activities throughout the option period. The primary objective of this procurement is to secure a reliable supply of Doxycycline Hyclate, a pharmaceutical product, for the DLA Troop Support’s operational needs. Contractors are expected to manufacture and deliver this medication in accordance with federal standards and the terms outlined in the contract. The intended outcome is to maintain uninterrupted access to this essential pharmaceutical, supporting the health and readiness of military personnel and other beneficiaries. The contracting entity is DLA Troop Support, a federal office within the Defense Logistics Agency. For inquiries or further information regarding the contract, interested parties may contact Courtney Hunter ([email protected], 445-737-3585) or Jason Wray ([email protected], 445-737-6304). The notice remains active and is accessible via the SAM.gov portal, with additional attachments available for review. This contract award represents a continuation of established procurement activities, with no changes to the scope, requirements, or deliverables beyond the extension of the performance period. Contractors specializing in pharmaceutical manufacturing, particularly those with experience in producing Doxycycline Hyclate, may find this opportunity aligns with their capabilities, provided they meet the stringent quality and regulatory standards required by the Department of Defense. For further details and official documentation, contractors are encouraged to consult the SAM.gov opportunity listing at https://sam.gov/opp/fd9cb19dfd0146f788e6ab453a2ce80f/view.